Health Care Roundup: Market Talk

A facts-only brief, written by a local AI model from this article in The Wall Street Journal, November 4, 2026. It may contain mistakes, and it is not the article: the full story is at wsj.com.

Organigram has agreed to acquire Aurora Cannabis for approximately C$561 million, a cash-and-stock deal that outbids a hostile offer from Curaleaf. The transaction values Aurora shares at C$7.80, representing a 21% premium over Curaleaf’s C$6.45 bid and a 93% premium over Aurora’s August price. British American Tobacco is providing a GBP100 million commitment, while a C$210 million credit facility supports the financing. Aurora stated the deal offers immediate valuation benefits and prevents a disruptive takeover battle, while Organigram cited the combination as supporting scale in Canadian and European markets. Aurora shares rose 20% to C$7.08 following the announcement.

Background

• Novo Nordisk reported third-quarter sales that exceeded expectations by 8% and operating profit by 12%, leading J.P. Morgan analysts to predict a 3% rise in consensus earnings expectations.
• Pfizer’s third-quarter results showed a 63% decline in Paxlovid sales and a 29% drop in Comirnaty sales, though Eliquis sales grew 25% and revenues from recently launched or acquired products increased 32%.
• Bayer raised its full-year adjusted Ebitda guidance by 200 million euros, a move Jefferies analysts attributed to the company projecting its third-quarter earnings beat forward.
• UBS cut its rating on Sonova to neutral, arguing that while the hearing aid maker’s fundamentals are strong, potential earnings upgrades are already priced into the stock.

Read the full article at wsj.com

More from Wednesday, November 4: